GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Appointment of Darren Cline as U.S. Chief Commercia...
April 11 2019 - 4:05PM
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the
Group), the world leader in the development and commercialization
of cannabinoid prescription medicines, today announced the
appointment of Darren Cline as its new U.S. Chief Commercial
Officer. Mr. Cline will lead the Epidiolex® U.S. commercial
organization and is expected to start on April 22, 2019. Mr. Cline
is succeeding Julian Gangolli who, as announced in November 2018,
is retiring and will work with Mr. Cline for several weeks as he
transitions into the organization.
Mr. Cline is an accomplished biopharmaceutical
executive with over 25 years of commercial experience and was
previously Executive Vice President, Commercial and a member of the
Executive Committee at Seattle Genetics, where he oversaw all
marketing, sales, and managed markets functions. He was directly
involved in the commercial build out for the launch of ADCETRIS®,
an antibody-based biologic the U.S. Food and Drug Administration
(FDA) approved for treatment of certain hematologic cancers. He was
instrumental in driving ADCETRIS’ continued revenue growth to over
$475 million in 2018. Prior to Seattle Genetics, Mr. Cline was at
Alexion Pharmaceuticals, where he was a key member of the initial
commercial leadership team that prepared the company for the
Soliris launch, helping to build out key sales functions that were
instrumental in Soliris becoming a billion-dollar brand. Mr Cline
also held commercial leadership positions at Intermune and Amgen.
Mr. Cline received his undergraduate degree from San Diego State
University and his MBA from Pepperdine University.
"We are delighted to have an executive of such
high caliber as Darren Cline join our team as the new U.S. Chief
Commercial Officer at GW. Darren brings significant commercial
experience and a proven track record in execution which will help
GW maximize the commercial opportunity of Epidiolex in the U.S. I
am confident he will build upon the company’s solid commercial
foundation and carry forward our ability to bring this much needed
new treatment to patients,” commented Justin Gover, GW’s Chief
Executive Officer. “I also want to offer our deepest thanks to
Julian Gangolli for his expert leadership in building a world-class
U.S. commercial organization from scratch and sheparding Epidiolex
through a successful launch. We wish him well in his
retirement.”
“I am very excited to join GW and to lead such a
talented U.S. commercial team,” said Cline. “Epidiolex is an
important new treatment that offers hope to many patients with
Lennox-Gastaut Syndrome and Dravet syndrome who are in desperate
need of new treatments to reduce their seizures. I look forward to
continuing to deliver on GW’s mission of bringing transformational
medicines to patients and building on the successful commercial
organization in place to maximize the Epidiolex opportunity.”
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. GW, along with
its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA
approval for EPIDIOLEX (cannabidiol) oral solution for the
treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
or Dravet syndrome in patients two years of age or older and which
is now available by prescription in the U.S. The Company has
submitted a regulatory application in Europe for the adjunctive
treatment of seizures associated with LGS and Dravet syndrome. The
company continues to evaluate EPIDIOLEX in additional rare epilepsy
conditions including tuberous sclerosis complex (TSC) and Rett
syndrome. GW commercialized the world’s first plant-derived
cannabinoid prescription drug, Sativex® (nabiximols), which is
approved for the treatment of spasticity due to multiple sclerosis
in numerous countries outside the United States and for which the
company is now planning a U.S. Phase 3 trial. The Company has a
deep pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 trials for epilepsy,
glioblastoma, and schizophrenia. For further information, please
visit www.gwpharm.com.
Forward-looking statementsThis
news release contains forward-looking statements that reflect GW's
current expectations regarding future events, including statements
regarding financial performance, the timing of clinical trials, the
timing and outcomes of regulatory or intellectual property
decisions, the relevance of GW products commercially available and
in development, the clinical benefits of EPIDIOLEX (cannabidiol)
oral solution and the safety profile and commercial potential of
EPIDIOLEX. Forward-looking statements involve risks and
uncertainties. Actual events could differ materially from those
projected herein and depend on a number of factors, including
(inter alia), the success of GW’s research strategies, the
applicability of the discoveries made therein, the successful and
timely completion and uncertainties related to the regulatory
process, and the acceptance of Sativex, EPIDIOLEX and other
products by consumer and medical professionals. A further list and
description of risks and uncertainties associated with an
investment in GW can be found in GW’s filings with the U.S.
Securities and Exchange Commission, including the most recent Form
10-KT filed on February 26, 2018. Existing and prospective
investors are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date hereof.
GW undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new
information, future events or circumstances or otherwise.
Enquiries:
GW Pharmaceuticals plc |
|
Stephen
Schultz, VP Investor Relations (U.S.) |
917 280 2424 / 401 500 6570 |
|
|
U.S. Media Enquiries:Sam Brown Inc.
Healthcare Communications |
|
Christy
CurranMike Beyer |
615 414 8668312 961 2502 |
|
|
EU Media Enquiries:FTI
Consulting |
|
Ben
Atwell/Andrew Ward |
+44 (0)
20 727 1000 |
|
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Sep 2023 to Sep 2024